PepGen Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ananda Ghosh from H.C. Wainwright maintained a Buy rating on the stock and has a $20.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ananda Ghosh has given his Buy rating due to a combination of factors that, in his view, de-risk PepGen’s DM1 program and enhance its upside potential. He interprets the modest average splicing correction at 5 mg/kg as being largely skewed by a single anomalous patient, while the remaining treated patients appear to show substantially stronger biological activity at this dose.
He also highlights that the clear drug accumulation in muscle tissue, together with the favorable safety profile and lack of concerning renal signals, suggests 5 mg/kg is a safe but sub-therapeutic entry point. As a result, he expects that the ongoing 10 mg/kg multiple-dose cohort could deliver materially higher splicing correction, potentially approaching levels seen in prior single-dose data, which he views as a key value inflection for the stock.
Ghosh covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Maze Therapeutics, Inc., and ACADIA Pharmaceuticals. According to TipRanks, Ghosh has an average return of 54.8% and a 62.32% success rate on recommended stocks.